Corcept Therapeutics (CORT) Research & Development (2010 - 2026)

Corcept Therapeutics has disclosed Research & Development across 17 years of filings, most recently posting $66.3 million for Q1 2026.

• Research & Development for Q1 2026 came in at $66.3 million, up 9.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $260.4 million (up 4.54% YoY), and the FY2025 annual result was $254.9 million, up 3.25% from the prior year.
• Research & Development came in at $66.3 million for Q1 2026 at Corcept Therapeutics, up from $64.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $70.3 million in Q4 2024 to a low of $28.1 million in Q1 2022.
• The 5-year median for Research & Development is $58.5 million (2024), against an average of $52.0 million.
• Across the five-year window, Research & Development jumped 48.85% in 2023 and fell 7.74% in 2025, its largest moves.
• Corcept Therapeutics' Research & Development stood at $36.8 million in 2022, then surged by 48.85% to $54.7 million in 2023, then increased by 28.5% to $70.3 million in 2024, then dropped by 7.74% to $64.9 million in 2025, then climbed by 2.17% to $66.3 million in 2026.
• The last three Research & Development figures came in at $66.3 million (Q1 2026), $64.9 million (Q4 2025), and $68.8 million (Q3 2025), per Business Quant data.